Standout Papers
- Birmingham Vasculitis Activity Score (BVAS) in systemic necrotizing vasculitis. (1994)
Citation Impact
Citing Papers
Neuropsychiatric applications of transcranial magnetic stimulation: a meta analysis
2002
Efficacy and Safety of Transcranial Magnetic Stimulation in the Acute Treatment of Major Depression: A Multisite Randomized Controlled Trial
2007 Standout
Membrane vesicles, current state-of-the-art: emerging role of extracellular vesicles
2011 Standout
EULAR recommendations for the use of imaging in large vessel vasculitis in clinical practice
2018 Standout
Intravenous pulse administration of cyclophosphamide versus daily oral treatment in patients with antineutrophil cytoplasmic antibody-associated vasculitis and renal involvement: A prospective, randomized study
1998
Prediction of relapses in Wegener's granulomatosis by measurement of antineutrophil cytoplasmic antibody levels: A prospective study
2000
EULAR recommendations for the management of primary small and medium vessel vasculitis
2008 Standout
Randomized trial of cyclophosphamide versus methotrexate for induction of remission in early systemic antineutrophil cytoplasmic antibody–associated vasculitis
2005
Soluble Receptors and Cytokine Antagonists in Human Milk
1996
Human Milk Composition
2012 Standout
A Critical Appraisal of Review Articles on the Effectiveness of Conservative Treatment for Neck Pain
2001 Standout
A Randomized Trial of Maintenance Therapy for Vasculitis Associated with Antineutrophil Cytoplasmic Autoantibodies
2003 Standout
Guidelines for the use of immunosuppressive drugs in patients with ocular inflammatory disorders: recommendations of an expert panel
2000 Standout
Acute kidney injury
2012 Standout
10 Disease assessment and management of the vasculitides
1997
Rituximab as rescue therapy in anti-neutrophil cytoplasmic antibody-associated vasculitis: a single-centre experience with 15 patients
2008
Small-Vessel Vasculitis
1997 Standout
Sjögren's syndrome
2005 Standout
Should We Expand the Toolbox of Psychiatric Treatment Methods to Include Repetitive Transcranial Magnetic Stimulation (rTMS)?
2010 Standout
Biologic therapy in primary systemic vasculitis of the young
2009
Intravenous immunoglobulin for ANCA-associated systemic vasculitis with persistent disease activity
2000
Efficacy and Safety of Sofosbuvir Plus Daclatasvir for Treatment of HCV-Associated Cryoglobulinemia Vasculitis
2017
Pulmonary infection in Wegener granulomatosis and idiopathic pulmonary fibrosis
2009
A prospective study of vasculitis patients collected in a five year period: evaluation of the Chapel Hill nomenclature
2000
Prospective Study of TNFα Blockade with Infliximab in Anti-Neutrophil Cytoplasmic Antibody-Associated Systemic Vasculitis
2004
Efficacy of Transcranial Magnetic Stimulation Targets for Depression Is Related to Intrinsic Functional Connectivity with the Subgenual Cingulate
2012 Standout
Churg‐Strauss syndrome with poor‐prognosis factors: A prospective multicenter trial comparing glucocorticoids and six or twelve cyclophosphamide pulses in forty‐eight patients
2007
Wegener's granulomatosis: A challenging disease for otorhinolaryngologists
2005
Hepatitis B Virus-Associated Polyarteritis Nodosa
2005
T lymphocytes in patients with primary vasculitis: expansion of CD8+ T cells with the propensity to activate polymorphonuclear neutrophils
2008
IgG subclass distribution, affinity of anti‐myeloperoxidase antibodies in sera from patients with Wegener's granulomatosis and microscopic polyangiitis
2008
The Generation of Donor-Specific CD4+CD25++CD45RA+ Naive Regulatory T Cells in Operationally Tolerant Patients After Pediatric Living-Donor Liver Transplantation
2010 StandoutNobel
Diagnostic role of endothelial microparticles in vasculitis
2008
Treatment of Antineutrophil Cytoplasm Autoantibody-Associated Systemic Vasculitis: Initiatives of the European Community Systemic Vasculitis Clinical Trials Study Group
1997
Transcranial magnetic stimulation in neurology
2003
Randomized Trial of Plasma Exchange or High-Dosage Methylprednisolone as Adjunctive Therapy for Severe Renal Vasculitis
2007
Biomarkers in systemic lupus erythematosus: II. Markers of disease activity
2004
Granulomatosis with Polyangiitis (Wegener's): An alternative name for Wegener's Granulomatosis
2011 Standout
Positive classic antineutrophil cytoplasmic antibody (C‐ANCA) titer at switch to azathioprine therapy associated with relapse in proteinase 3–related vasculitis
2004
Modification and validation of the Birmingham Vasculitis Activity Score (version 3)
2008
Safety, ethical considerations, and application guidelines for the use of transcranial magnetic stimulation in clinical practice and research
2009 Standout
Human FoxP3+ regulatory T cells in systemic autoimmune diseases
2011 StandoutNobel
Elevated relapse rate under oral methotrexate versus leflunomide for maintenance of remission in Wegener's granulomatosis
2007
15-Deoxyspergualin in Patients with Refractory ANCA-Associated Systemic Vasculitis
2003
Long‐term comparison of rituximab treatment for refractory systemic lupus erythematosus and vasculitis: Remission, relapse, and re‐treatment
2006
Examination of disease severity in systemic vasculitis from the novel perspective of damage using the vasculitis damage index (VDI)
1998
Prediction of relapses in PR3-ANCA-associated vasculitis by assessing responses of ANCA titres to treatment
2006
A randomized controlled trial of rituximab following failure of antiviral therapy for hepatitis C virus–associated cryoglobulinemic vasculitis
2011
An interdisciplinary approach to the care of patients with Wegener's granulomatosis: Long-term outcome in 155 patients
2000 Standout
Functional defect of circulating regulatory CD4+ T cells in patients with Wegener's granulomatosis in remission
2007
Idiopathic pulmonary fibrosis
2017 Standout
Intravenous immunoglobulins for relapses of systemic vasculitides associated with antineutrophil cytoplasmic autoantibodies: Results of a multicenter, prospective, open‐label study of twenty‐two patients
2007
Analysis of factors predictive of survival based on 49 patients with systemic Wegener's granulomatosis and prospective follow‐up
2001
Patients with Wegener’s granulomatosis demonstrate a relative deficiency and functional impairment of T‐regulatory cells
2010
Effectiveness of TNF-alpha blockade with infliximab in refractory Wegener's granulomatosis
2002
Persistent expansion of CD4+ effector memory T cells in Wegener's granulomatosis
2006
A multicenter survey of rituximab therapy for refractory antineutrophil cytoplasmic antibody–associated vasculitis
2009
Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2010
2011 Standout
Polarization of Tumor-Associated Neutrophil Phenotype by TGF-β: “N1” versus “N2” TAN
2009 Standout
Inflammation and arterial stiffness in systemic vasculitis: A model of vascular inflammation
2004
Differential B- and T-cell activation in Wegener’s granulomatosis
1999
Effects of cyclophosphamide on the development of malignancy and on long‐term survival of patients with rheumatoid arthritis a 20‐year followup study
1995
Therapy for the maintenance of remission in sixty‐five patients with generalized Wegener's granulomatosis. Methotrexate versus trimethoprim/sulfamethoxazole
1996
Primary systemic vasculitis
1997
The target antigens of antineutrophil cytoplasmic antibodies (ANCA) induced by propylthiouracil
2006
Etanercept combined with conventional treatment in Wegener's granulomatosis: A six-month open-label trial to evaluate safety
2001
ANCA Disease
2010
Lack of efficacy of rituximab in Wegener's granulomatosis with refractory granulomatous manifestations
2005
Increase of circulating neutrophil and platelet microparticles during acute vasculitis and hemodialysis
2006
Rituximab versus Cyclophosphamide in ANCA-Associated Renal Vasculitis
2010 Standout
Renal survival and prognostic factors in patients with PR3-ANCA associated vasculitis with renal involvement
2003
Transcranial Magnetic Stimulation: A Primer
2007 Standout
Induction of remission in active anti-neutrophil cytoplasmic antibody-associated vasculitis with mycophenolate mofetil in patients who cannot be treated with cyclophosphamide
2006
Development and initial validation of the vasculitis damage index for the standardized clinical assessment of damage in the systemic vasculitides
1997
BSR and BHPR guidelines for the management of adults with ANCA associated vasculitis
2007
Invasive Pulmonary Aspergillosis in Patients With Antineutrophil Cytoplasmic Antibody Associated Vasculitis
2009
Expert consensus document on arterial stiffness: methodological issues and clinical applications
2006 Standout
Long-term followup of polyarteritis nodosa, microscopic polyangiitis, and Churg-Strauss syndrome: Analysis of four prospective trials including 278 patients
2001
Mycophenolate Mofetil for Maintenance Therapy of Wegener's Granulomatosis and Microscopic Polyangiitis
1999
Long-term patient survival in ANCA-associated vasculitis
2010 Standout
CHRONIC NECK PAIN
1996
Epidemiology of Wegener's granulomatosis in Northern Norway
2000
Polyarteritis nodosa when applying the Chapel Hill nomenclature--a descriptive study on ten patients
2006
Development and validation of a consensus methodology for the classification of the ANCA-associated vasculitides and polyarteritis nodosa for epidemiological studies
2006 Standout
Rituximab for Refractory Wegener's Granulomatosis
2005
2016 American Thyroid Association Guidelines for Diagnosis and Management of Hyperthyroidism and Other Causes of Thyrotoxicosis
2016 Standout
Guidelines on the Use of Therapeutic Apheresis in Clinical Practice – Evidence‐Based Approach from the Writing Committee of the American Society for Apheresis: The Eighth Special Issue
2019 Standout
An approach to the diagnosis and management of systemic vasculitis
2010
The Role of Ultrasound Compared to Biopsy of Temporal Arteries in the Diagnosis and Treatment of Giant Cell Arteritis (TABUL): a diagnostic accuracy and cost-effectiveness study
2016
Abnormalities of CD4+ T cell subpopulations in ANCA-associated vasculitis
2005
T lymphocyte responses to anti-neutrophil cytoplasmic autoantibody (ANCA) antigens are present in patients with ANCA-associated systemic vasculitis and persist during disease remission
1998
Special Issue: KDIGO Clinical Practice Guideline for the Care of Kidney Transplant Recipients
2009 Standout
Effects of anti-CD20 monoclonal antibody as a rescue treatment for ANCA-associated idiopathic systemic vasculitis with or without overt renal involvement.
2009
Practice Guidelines for the Diagnosis and Management of Aspergillosis: 2016 Update by the Infectious Diseases Society of America
2016 Standout
Pulse Versus Daily Oral Cyclophosphamide for Induction of Remission in Antineutrophil Cytoplasmic Antibody—Associated Vasculitis
2009
EASL Recommendations on Treatment of Hepatitis C 2018
2018 Standout
Regulatory T cell and autoimmune diseases
2005 StandoutNobel
Marine Polysaccharides from Algae with Potential Biomedical Applications
2015 Standout
TNF‐mediated inflammatory disease
2007 Standout
Addition of Plasma Exchange to Glucocorticosteroids for the Treatment of Severe Henoch-Schönlein Purpura in Adults: A Case Series
2012
Works of B Janssen being referenced
The Role of Motor Evoked Potentials in Psychogenic Paralysis
1995
CORRELATION OF BLOOD LEVELS OF SOLUBLE VASCULAR CELL ADHESION MOLECULE-1 WITH DISEASE ACTIVITY IN SYSTEMIC LUPUS ERYTHEMATOSUS AND VASCULITIS
1994
The Neurologic Workup in Patients with Cervical Spine Disorders
1990
Birmingham Vasculitis Activity Score (BVAS) in systemic necrotizing vasculitis.
1994 Standout
Prospective pilot study of intravenous pulse cyclophosphamide therapy for refractory rheumatoid arthritis
1989